Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refractory tumor models
These findings provide a rationale for the combination of STAR0602 and SOC therapy in the clinical setting for patients with recurrent or metastatic HPV<sup>-</sup> HNSCC.
Authors
- Kellsye P. Fabian (ORCID: https://orcid.org/0000-0002-0273-5647)
- James W. Hodge (ORCID: https://orcid.org/0000-0001-5282-3154)
- Andrew Bayliffe (ORCID: https://orcid.org/0000-0002-7892-9210)
- Michelle R. Padget (ORCID: https://orcid.org/0000-0003-4922-1042)
- Francesca Rosato (ORCID: https://orcid.org/0000-0002-9255-9391)
- Jacques Moisan (ORCID: https://orcid.org/0009-0009-8563-278X)
- Ginette S. Santiago-Sánchez (ORCID: https://orcid.org/0000-0002-0615-4583)
- Jeffrey Schlom (ORCID: https://orcid.org/0000-0001-7932-4072)
- Clint Allen (ORCID: https://orcid.org/0000-0001-6586-5804)
- Zhen Su (ORCID: https://orcid.org/0009-0004-4932-8573)
- J Lee
- Madan Katragadda (ORCID: https://orcid.org/0009-0004-2394-6816)
Institutions
- National Institutes of Health (US)
- National Cancer Institute (US)
- Center for Cancer Research (US)
- Io Therapeutics (United States) (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/jitc-2025-013158
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00